Hansoh Pharma

Hansoh Pharma, established in 1995, is a leading innovation-driven pharmaceutical company in China. Upholding the corporate mission of "Optimizing ethnic medicine and strengthening Chinese innovation," the company is committed to improving human health through continuous innovation, with a focus on major therapeutic areas such as oncology, central nervous system, anti-infectives, and diabetes. The company has consistently ranked among the top 30 in the Top 100 Pharmaceutical Companies in China's pharmaceutical industry for several years and among the top three in the Best Industrial Enterprises in R&D Pipeline in China. It is a key national high-tech enterprise and a national technology innovation demonstration enterprise. The company was listed on the Hong Kong Stock Exchange (HK.03692) in June 2019. Hansoh Pharma boasts excellent R&D capabilities and over 20 years of R&D experience. It has established R&D centers in Maryland, USA, and in Shanghai, Lianyungang, and Changzhou in China, covering the entire R&D process from cutting-edge information collection, compound design and screening, pharmacological and toxicological studies to pilot-scale production. The company has also created multiple national-level R&D institutions, including a National Enterprise Technology Center, a Postdoctoral Research Station, and a National-Local Joint Engineering Center for Long-Acting Peptide Drugs. The company actively cultivates and recruits high-level technical talent. As of December 2020, it had more than 1,600 professional R&D personnel and had undertaken more than 50 national scientific research projects, including the 863 Program, the Major New Drug Creation Science and Technology Project, and the Torch Program. It has won two second prizes of the National Science and Technology Progress Award, one China Patent Gold Award, and more than 300 authorized invention patents both domestically and internationally. It has participated in setting nearly 150 national standards. After more than 20 years of continuous R&D investment, the company has launched five Class 1 innovative drugs, with over a hundred drugs in development and more than 20 innovative drugs entering clinical trials, forming a rich pipeline. In June 2021, the company's self-developed first original Chinese oral anti-hepatitis B virus (HBV) drug, Hengmu® (Amitinofuvir Tablets), was approved for marketing for the treatment of adult patients with chronic hepatitis B. This marked a significant breakthrough in the development of urgently needed new drugs in the clinic, showing advantages in efficacy, safety, and stability, which is beneficial for addressing unmet clinical needs of hepatitis B patients. Amileta® (Afatinib Mesylate Tablets), approved for marketing in March 2020, is the first third-generation EGFR-TKI innovative drug independently developed by Hansoh Pharma in China, used for treating non-small cell lung cancer and solving the T790M resistance problem. It is also the world's first third-generation EGFR-TKI with a median progression-free survival (mPFS) exceeding one year (for second-line use). This provides clinicians with a potent, safe, and accessible new option, bringing hope for long-term, high-quality survival for more advanced non-small cell lung cancer patients. Hansoxin® (Flumatinib Mesylate Tablets) is the first independently developed novel second-generation chronic myeloid leukemia innovative drug in China, optimizing both efficacy and safety, significantly improving patients' quality of life during their disease course. Fulaimai® (Polyethylene Glycol Lusenetide Injection) is China’s first self-innovated long-acting GLP-1 class hypoglycemic drug and the world’s first PEGylated long-acting hypoglycemic drug. With clear hypoglycemic effects, high safety, and only requiring once-weekly injections, it offers a new medication option for Chinese diabetes patients. Milinda® (Morinidazole Sodium Chloride Injection) is the world’s first nitroimidazole-class innovative drug against anaerobic bacteria in 40 years, offering better efficacy and higher safety. Additionally, Hansoh Pharma always maintains dynamic alignment with global advanced access levels, continuously designing and building production facilities and production lines according to international advanced standards and using advanced production equipment. The company’s production quality system has obtained official certifications from the US FDA, EU EMA, and Japan PMDA, allowing finished formulations and active pharmaceutical ingredients to be sold to countries and regions such as Europe, the US, and Japan. Hansoh Pharma adheres to patient benefit-centered and clinically data-oriented pharmaceutical services, focusing on academic dissemination of drug clinical effects and medication characteristics. Through clinical and pharmacovigilance research, it enhances medical professionals’ understanding of drug safety and efficacy, promoting progress in clinical medication. In the future, upholding the corporate mission of "Optimizing ethnic medicine and strengthening Chinese innovation," Hansoh Pharma will accelerate its pace of technological innovation, continue to focus on meeting unmet clinical medical needs, and continuously introduce more innovative drugs to improve human health and quality of life.